Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...
Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...
A Brazilian research team has eliminated HIV from a patient’s body for 78 consecutive weeks using only medications, without ...
Eswatini has become the first African country to receive lenacapavir, a twice-yearly HIV prevention injection that global ...
To put this spike into perspective, the rural city of around 32,000 people has now recorded more HIV cases in two years than ...
Last year, 444 people in the Netherlands were diagnosed with HIV, the virus that can cause AIDS. Almost 20 years ago, there ...
The drug lenacapavir will be distributed to Eswatini and Zambia — the first step toward providing at least 2 million doses to ...
Infections, including influenza, COVID-19, HIV, hepatitis C and herpes zoster, can raise the risk of cardiovascular disease (CVD), and vaccines could help lower that risk, according to a study ...
Trump administration touts moves to provide HIV prevention drug, but refuses to include South Africa
The US has started to provide doses of a Gilead HIV prevention drug to low-income countries, but the program will not include ...
About 1,000 doses of Gilead Sciences Inc's drug lenacapavir were delivered to Zambia and Eswatini last Thursday, U.S. and ...
Merck (MRK) stock gains as new oral HIV tablet matches Gilead's (GILD) three-drug once-daily HIV pill Biktarvy in a Phase 3 ...
Patients with and without HIV had similar 1- and 3-year survival outcomes following kidney transplantation, however, 5-year survival outcomes differed significantly.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback